

## **Title: Screening Failures: How to improve coverage of vaccination?**

**Authors:** Antonio-E. Ngua Roca<sup>1,2</sup>, Vicente Urbano<sup>1,4</sup>, Esther Eburi<sup>1,2</sup>, Stephen R. Manock<sup>1,5</sup>, Martin Eka Ondo Mangué<sup>1,4</sup>, Carlos Cortes Falla<sup>1,2</sup>, Matilde Riloha Rivas<sup>2</sup>, Stephen L. Hoffman<sup>5</sup>, Salim Abdulla<sup>3</sup>

1=Equatorial Guinea Malaria Vaccine Initiative; 2=Medical Care Development International; 3=Ifakara Health Institute; 4=Equatorial Guinea Ministry of Health and Social Welfare; 5=Sanaria Inc.

Evaluation of the PfSPZ vaccine has been conducted in Equatorial Guinea (EG) since 2015. A Phase I and a Phase II trial has been completed. Currently preparations are ongoing to conduct a Phase II and Phase III trial in EG. As part of the preparatory activities an assessment will be done on the proportion and profile of potential trial subjects excluded from enrolment based on inclusion and exclusion criteria set for the two trials. The potential participants of the two trials will be invited for screening and detailed information about health history and social background will be collected. Physical examination will be done and blood samples collected for laboratory analysis. Based on the protocol guidelines and eligibility criteria eligible will be invited for enrollment. Participants excluded prior to any vaccination are considered as “screening failures” and the reasons for their exclusion are various. Data from the screening failures will be analyzed in comparison to those enrolled and the total number of screened participants to gain insight on the contributing factors for non-participation for individuals who consider themselves healthy in the community. The proportions of screening failures will be calculated and categorized with respect to age group and reason(s) for exclusion. These will be extrapolated to get an estimate of how many people on the Island of Bioko would potentially *not* be eligible for future biomedical research like a vaccine study. The implication of the screening failures on the logistics of the conduct of the trials and potential options for optimizing recruitment for the trials or any additional supportive measures will be discussed.